Sanibel Captiva Trust Company Inc. Increases Stake in Novo Nordisk A/S (NYSE:NVO)

Sanibel Captiva Trust Company Inc. raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 73.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,568 shares of the company’s stock after buying an additional 6,575 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Novo Nordisk A/S were worth $1,339,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Strategic Investment Solutions Inc. IL purchased a new stake in Novo Nordisk A/S during the 2nd quarter worth about $25,000. Daiwa Securities Group Inc. purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $28,000. Capital Performance Advisors LLP purchased a new position in Novo Nordisk A/S in the third quarter worth approximately $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $48,000. Finally, M&R Capital Management Inc. increased its position in shares of Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after purchasing an additional 297 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 5.2 %

NVO stock opened at $78.74 on Friday. The company has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a fifty day moving average price of $97.76 and a 200 day moving average price of $117.23. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Wall Street Analyst Weigh In

NVO has been the subject of several recent analyst reports. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.